Press Releases Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Market Closed - Nasdaq Other stock markets 01:30:00 09/05/2024 am IST			5-day change	1st Jan Change
22.38 ^USD	-3.45%		+1.87%	+3.56%

08/05	Syndax Pharmaceuticals Q1 Net Loss Widens	MT
08/05	Transcript : Syndax Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Syndax Pharmaceuticals : First Quarter 2024 Conference Call	08/05	PU
Syndax: Q1 Earnings Snapshot	08/05	AQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	04/05	PR
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024	01/05	PR
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum	11/04	PR
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed, Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	09/04	AQ
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	06/04	PR
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed, Refractory KMT2Ar Acute Leukemia	27/03	AQ
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer	18/03	PR
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	02/03	PR
Syndax: Q4 Earnings Snapshot	28/02	AQ
Syndax Announces Participation at Two Upcoming Investor Conferences	26/02	PR
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024	21/02	PR
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	03/02	PR
Syndax Announces Participation at Two Upcoming Investor Conferences	02/02	PR
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	06/01	PR
Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference	03/01	PR
Syndax Highlights Recent Updates and Anticipated 2024 Milestones	02/01	AQ
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters Option to Purchase Additional Shares	20/12	AQ
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares	20/12	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Press Releases

Filters